CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation. BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading ...